Head-To-Head Review: RushNet (OTCMKTS:RSHN) versus Danaher (NYSE:DHR)

RushNet (OTCMKTS:RSHN) and Danaher (NYSE:DHR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Analyst Ratings

This is a summary of recent ratings and recommmendations for RushNet and Danaher, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RushNet	0	0	0	0	N/A
Danaher	0	6	9	0	2.60

Danaher has a consensus price target of $266.00, indicating a potential upside of 6.90%. Given Danaher’s higher probable upside, analysts clearly believe Danaher is more favorable than RushNet.

Valuation & Earnings

This table compares RushNet and Danaher’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RushNet	N/A	N/A	N/A	N/A	N/A
Danaher	$23.89 billion	7.70	$4.76 billion	$6.39	38.94

Danaher has higher revenue and earnings than RushNet.

Institutional & Insider Ownership

79.1% of Danaher shares are held by institutional investors. 11.1% of Danaher shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares RushNet and Danaher’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RushNet	N/A	N/A	N/A
Danaher	17.26%	12.25%	7.43%

Summary

Danaher beats RushNet on 8 of the 8 factors compared between the two stocks.

About RushNet

RushNet, Inc. provides laboratory diagnostic testing services. It offers high-complexity urine drug testing, behavioral drug testing, allergy droplet cards, oral fluids, and infectious disease services. The company is based in Jacksonville, Florida.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.